Treatment for Middle Insomnia (Sleep Maintenance Insomnia)
Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for middle insomnia in adults, with multicomponent CBT-I being strongly recommended over all other approaches. 1
Treatment Algorithm
First-Line: Behavioral/Psychological Therapy
Start with multicomponent CBT-I as the primary treatment for chronic sleep maintenance insomnia 1. This is the only STRONG recommendation from the American Academy of Sleep Medicine guidelines and should be implemented before considering pharmacotherapy.
- Components include: sleep restriction therapy, stimulus control, relaxation techniques, and cognitive restructuring
- Alternative behavioral options if full CBT-I is unavailable:
Important caveat: Sleep hygiene alone should NOT be used as single-component therapy 1
Second-Line: Pharmacologic Therapy
When behavioral interventions are insufficient or unavailable, pharmacologic options specifically recommended for sleep maintenance insomnia include:
Preferred Pharmacologic Agents for Middle Insomnia:
Suvorexant (orexin receptor antagonist) - Specifically indicated for sleep maintenance insomnia 2
- Doses: 10,15/20, or 20 mg
- Mechanism targets wakefulness promotion system
- Well-tolerated with favorable safety profile 3
Doxepin (low-dose heterocyclic) - Specifically indicated for sleep maintenance insomnia 2
- Doses: 3 mg or 6 mg
- Histamine receptor antagonist at low doses
- Effective for maintaining sleep without significant next-day impairment 3
Eszopiclone (benzodiazepine receptor agonist) - Indicated for both sleep onset AND maintenance 2
- Doses: 2 mg or 3 mg
- Addresses both initiation and maintenance problems
Zolpidem (standard or extended-release) - Indicated for both sleep onset AND maintenance 2
- Dose: 10 mg
- Extended-release formulation particularly useful for maintenance issues 3
Temazepam (benzodiazepine) - Indicated for both sleep onset AND maintenance 2
- Dose: 15 mg
- Use with caution due to benzodiazepine risks
Agents to AVOID:
All recommendations below are to NOT use these agents 2:
- Trazodone - Despite common off-label use, not recommended
- Melatonin - Not effective for sleep maintenance
- Diphenhydramine - Not recommended despite OTC availability
- Tiagabine - Not effective
- Tryptophan - Not recommended
- Valerian - Not recommended
Clinical Decision-Making Framework
Step 1: Establish diagnosis using ICSD-3 or DSM-5 criteria for chronic insomnia disorder with sleep maintenance difficulties 1
Step 2: Implement multicomponent CBT-I as first-line therapy 1
Step 3: If CBT-I is inaccessible or insufficient after adequate trial, consider pharmacotherapy:
- For pure sleep maintenance insomnia: Suvorexant or low-dose doxepin are the most specific options 2, 3
- For combined sleep onset and maintenance: Eszopiclone or zolpidem extended-release 2, 3
- For middle-of-the-night awakenings: Low-dose sublingual zolpidem or zaleplon can be used 3, 4
Step 4: Use minimum effective doses and shortest duration necessary
Important Caveats
All pharmacologic recommendations carry WEAK strength under GRADE methodology 2, reflecting the evidence quality limitations in pharmaceutical trials (funding bias, small trial numbers, heterogeneity). This underscores why behavioral therapy with STRONG recommendation should be prioritized.
Age considerations: In elderly patients (>65 years), exercise particular caution with benzodiazepines and Z-drugs due to fall risk, cognitive impairment, and other adverse effects 3, 5. Prefer suvorexant, low-dose doxepin, ramelteon, or dual orexin receptor antagonists in this population 5.
Duration of therapy: Benzodiazepines and Z-drugs should not be prescribed for longer than 28 days due to dependence risk 6. CBT-I provides more durable benefits without these limitations.
Common pitfall: Clinicians often jump directly to pharmacotherapy due to accessibility issues with CBT-I 7, 6. However, emerging digital CBT-I platforms and home-based programs are increasing access to first-line behavioral treatment 7.